Newsfeeds - Spark Newswire

4 minute read

Aileron Therapeutics Highlights Presentation Of ALRN-6924 Clinical Data At ESMO Virtual Congress 2021

Today, 4:59 AM

Final results from completed Phase 1b trial in patients with small cell lung cancer (SCLC) receiving second-line topotecan demonstrated ALRN-6924's ability to reduce neutropenia, thrombocytopenia and anemia caused

ALRN

1 minute read

12 Health Care Stocks Moving In Tuesday’s Pre-Market Session

By Benzinga Insights

Today, 4:59 AM

ALRN

4 minute read

The Week Ahead In Biotech (Sept. 12-18): Calliditas FDA Decision, Adcom Review For Pfizer/BioNTech COVID-19 Vaccine, Oncology Conference And IPOs

By Shanthi Rexaline

Today, 4:59 AM

Biotech stocks retreated in the holiday-shortened week ending Sept. 10, reversing course from the previous week.

ALRN

1 minute read

Aileron Unveils Initial Data For Its Chemo Protective Agent

By Vandana Singh

Today, 4:59 AM

Aileron Therapeutics Inc (NASDAQ:ALRN) has announced initial findings from its ongoing study of ALRN-6924 in healthy volunteers. Data were presented at…

ALRN

4 minute read

The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer’s Drug

By Shanthi Rexaline

Today, 4:59 AM

ere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24)

AGEN

3 minute read

21 Stocks Moving in Wednesday’s Pre-Market Session

By Lisa Levin

Today, 4:59 AM

Gainers Regencell Bioscience Holdings Limited (NASDAQ: RGC) rose 40.1% to $21.43 in pre-market trading after gaining over 11% on Tuesday. Regencell Bioscience recently reported partial exercise of underwriter’s over-allotment option.

ACST

2 minute read

The Week Ahead In Biotech: Cara FDA Decision, Ascendis Earnings, Aileron Data Presentation And More

By Shanthi Rexaline

Today, 4:59 AM

Biotech stocks swayed back and forth before ending the week lower. With earnings news dying down and an empty initial public offerings calendar, it was broader market cues, clinical readouts and regulatory actions that moved stocks during the week.

ABVC

1 minute read

Aileron Launches Early-Stage Study For Chemoprotective Candidate In Lung Cancer Settings

By Vandana Singh

Today, 4:59 AM

Aileron Therapeutics Inc (NASDAQ:ALRN) has initiated Phase 1b trial of ALRN-6924 as a chemoprotective agent to treat patients with non-small cell…

ALRN

1 minute read

Uncategorized

Aileron Therapeutics Q1 EPS $(0.08) Up From $(0.24) YoY

By Bill Haddad

Today, 4:59 AM

Aileron Therapeutics (NASDAQ:ALRN) reported quarterly losses of $(0.08) per share. This is a 66.67 percent increase over losses of $(0.24) per share from the same period last year.

ALRN